Lasofoxifene in Phase III nears full enrollment for ESR1-mutated breast cancer
LeonaBio’s lasofoxifene is advancing in a pivotal Phase III trial in ESR1-mutated metastatic breast cancer, with enrollment nearing completion.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.